Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224373 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
A Phase 1 study of Multiple Sclerosis, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 13
- Study locations
NCT07224373: Recruiting Phase 1 study of Multiple Sclerosis, sponsored by AstraZeneca.
NCT07224373 is a Phase 1 study of Multiple Sclerosis that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 24 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224373, a Phase 1 study of Multiple Sclerosis, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 13
- Study locations
Study Summary
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
Primary Outcome
Incidence and severity of Dose Limiting Toxicity (DLT) over 104 weeks following AZD0120 administration.
Conditions Studied
Interventions
- BIOLOGICAL AZD0120 - Regimen 1
- BIOLOGICAL AZD0120 - Regimen 2
Study Locations (13)
Other
- Research Site - Liverpool
- Research Site - Melbourne
- Research Site - Waratah
New York
- Research Site - New York
- Research Site - New York
Arizona
- Research Site - Tucson
Colorado
- Research Site - Aurora
District of Columbia
- Research Site - Washington D.C.
Missouri
- Research Site - St Louis
Ohio
- Research Site - Cleveland
Washington
- Research Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2028-12-07 |
| Phase | Phase 1 |
What NCT07224373 shows while recruiting
NCT07224373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which AZD0120 - Regimen 1 is the first listed.
NCT07224373 lists 13 locations in 10 states (Other, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT07224373 about?
NCT07224373 is a clinical study titled "An Open-label Study of AZD0120 in Adults With Multiple Sclerosis". This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
What is the current status of trial NCT07224373?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-12-09. Estimated completion is 2028-12-07.
What conditions does trial NCT07224373 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT07224373?
The interventions under investigation include: AZD0120 - Regimen 1 (BIOLOGICAL), AZD0120 - Regimen 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07224373?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224373 being conducted?
This trial has 13 study locations across Arizona, Colorado, District of Columbia, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224373's enrollment target sits among peer trials
24 246th of 315 higher than 63 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI